Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.38
NAS:ILMN's Cash to Debt is ranked lower than
51% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NAS:ILMN: 1.38 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ILMN' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 1.85 Max: No Debt
Current: 1.38
Equity to Asset 0.52
NAS:ILMN's Equity to Asset is ranked lower than
62% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NAS:ILMN: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ILMN' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.56 Max: 0.94
Current: 0.52
0.36
0.94
Interest Coverage 15.60
NAS:ILMN's Interest Coverage is ranked lower than
59% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NAS:ILMN: 15.60 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ILMN' s Interest Coverage Range Over the Past 10 Years
Min: 3.38  Med: 5.73 Max: 67.52
Current: 15.6
3.38
67.52
F-Score: 6
Z-Score: 10.13
M-Score: -2.65
WACC vs ROIC
7.06%
27.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.55
NAS:ILMN's Operating margin (%) is ranked higher than
92% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NAS:ILMN: 24.55 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ILMN' s Operating margin (%) Range Over the Past 10 Years
Min: -82.12  Med: 18.88 Max: 27.65
Current: 24.55
-82.12
27.65
Net-margin (%) 18.70
NAS:ILMN's Net-margin (%) is ranked higher than
90% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NAS:ILMN: 18.70 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ILMN' s Net-margin (%) Range Over the Past 10 Years
Min: -75.89  Med: 12.01 Max: 21.65
Current: 18.7
-75.89
21.65
ROE (%) 22.55
NAS:ILMN's ROE (%) is ranked higher than
91% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NAS:ILMN: 22.55 )
Ranked among companies with meaningful ROE (%) only.
NAS:ILMN' s ROE (%) Range Over the Past 10 Years
Min: -84.48  Med: 10.45 Max: 27.88
Current: 22.55
-84.48
27.88
ROA (%) 11.44
NAS:ILMN's ROA (%) is ranked higher than
85% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NAS:ILMN: 11.44 )
Ranked among companies with meaningful ROA (%) only.
NAS:ILMN' s ROA (%) Range Over the Past 10 Years
Min: -43.21  Med: 5.8 Max: 19.92
Current: 11.44
-43.21
19.92
ROC (Joel Greenblatt) (%) 95.29
NAS:ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NAS:ILMN: 95.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ILMN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -508.83  Med: 75.57 Max: 136.47
Current: 95.29
-508.83
136.47
Revenue Growth (3Y)(%) 20.10
NAS:ILMN's Revenue Growth (3Y)(%) is ranked higher than
89% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NAS:ILMN: 20.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ILMN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1  Med: 29.9 Max: 156.2
Current: 20.1
-1
156.2
EBITDA Growth (3Y)(%) 27.40
NAS:ILMN's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NAS:ILMN: 27.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ILMN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.6  Med: 22.8 Max: 608.3
Current: 27.4
-73.6
608.3
EPS Growth (3Y)(%) 40.00
NAS:ILMN's EPS Growth (3Y)(%) is ranked higher than
84% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NAS:ILMN: 40.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ILMN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.7  Med: 8.9 Max: 209.1
Current: 40
-40.7
209.1
» NAS:ILMN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ILMN Guru Trades in Q3 2015

John Griffin 1,015,000 sh (New)
Frank Sands 4,334,855 sh (+63.44%)
RS Investment Management 81,270 sh (+38.73%)
Julian Robertson 158,500 sh (+32.19%)
Jim Simons 123,218 sh (+29.54%)
Vanguard Health Care Fund 3,025,105 sh (+26.02%)
First Eagle Investment 400 sh (unchged)
Paul Tudor Jones 1,300 sh (unchged)
PRIMECAP Management 2,178,040 sh (-2.74%)
Ron Baron 1,458,569 sh (-3.35%)
Stanley Druckenmiller 155,800 sh (-24.55%)
John Burbank 15,838 sh (-27.59%)
Steve Mandel 3,609,735 sh (-36.43%)
Andreas Halvorsen 1,789,486 sh (-63.99%)
» More
Q4 2015

ILMN Guru Trades in Q4 2015

George Soros 2,100 sh (New)
Frank Sands 6,091,448 sh (+40.52%)
Steve Mandel 3,609,835 sh (unchged)
First Eagle Investment 400 sh (unchged)
Samuel Isaly 180,000 sh (unchged)
Andreas Halvorsen Sold Out
John Burbank Sold Out
Paul Tudor Jones Sold Out
John Griffin Sold Out
Stanley Druckenmiller Sold Out
Jim Simons Sold Out
PRIMECAP Management 2,174,180 sh (-0.18%)
Ron Baron 1,404,071 sh (-3.74%)
Vanguard Health Care Fund 2,787,466 sh (-7.86%)
Julian Robertson 103,200 sh (-34.89%)
RS Investment Management 14,300 sh (-82.40%)
» More
Q1 2016

ILMN Guru Trades in Q1 2016

PRIMECAP Management 2,174,770 sh (+0.03%)
First Eagle Investment 400 sh (unchged)
Vanguard Health Care Fund 2,787,466 sh (unchged)
Samuel Isaly 180,000 sh (unchged)
George Soros Sold Out
Julian Robertson Sold Out
Frank Sands 5,606,751 sh (-7.96%)
Ron Baron 1,228,286 sh (-12.52%)
RS Investment Management 9,840 sh (-31.19%)
Steve Mandel 1,675,158 sh (-53.59%)
» More
Q2 2016

ILMN Guru Trades in Q2 2016

Steven Cohen 200 sh (New)
Frank Sands 6,649,580 sh (+18.60%)
Vanguard Health Care Fund 3,030,566 sh (+8.72%)
First Eagle Investment 400 sh (unchged)
Samuel Isaly 180,000 sh (unchged)
Steve Mandel Sold Out
PRIMECAP Management 2,139,920 sh (-1.60%)
Ron Baron 1,001,656 sh (-18.45%)
RS Investment Management 7,540 sh (-23.37%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:BAX, OTCPK:ESLOY, NYSE:BCR, OTCPK:CLPBY, OTCPK:TRUMY, NYSE:BDX, NAS:XRAY, NYSE:WAT, OTCPK:OCPNY, NYSE:MTD, NAS:HOLX, NYSE:RMD, NYSE:COO, NYSE:STE, NAS:SIRO, OTCPK:SAUHF, NYSE:WST, OTCPK:GNGBY, NYSE:HRC, NYSE:CMN » details
Traded in other countries:ILU.Germany, ILMN.Mexico,
Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

Illumina Inc was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response. The Company's customers include genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. The Company's portfolio of integrated systems, consumables and analysis tools is designed to accelerate and simplify genetic analysis. This portfolio addresses genomic complexity, price points and throughput, enabling customers to select the solution for their research or clinical challenge. It also provides products and services for other life sciences applied markets such as agrigenomics. Government and corporate researchers use its sequencing and array-based tools to accelerate and enhance agricultural research. In addition to selling products, the company provides genotyping, NIPT, and whole-genome sequencing services. The Company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In each of these areas, dedicated sales, service, and application-support personnel are expanding and supporting their respective customer bases. In addition, it sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and South Africa. The manufacturing operations require a wide variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. Multiple commercial sources provide many of its components and supplies, but there are some raw materials and components that the company obtains from single-source suppliers. The Company's competitors include Affymetrix, Inc., Agilent Technologies, Inc., BGI, Pacific Biosciences of California, Inc., QIAGEN N.V., Roche Holding AG., and Thermo Fisher Scientific, Inc., among others. The Company's operations are regulated by governmental authorities and FDA in the United State.

Ratios

vs
industry
vs
history
P/E(ttm) 61.17
ILMN's P/E(ttm) is ranked lower than
83% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.50 vs. ILMN: 61.17 )
Ranked among companies with meaningful P/E(ttm) only.
ILMN' s P/E(ttm) Range Over the Past 10 Years
Min: 34.06  Med: 76.15 Max: 332.54
Current: 61.17
34.06
332.54
Forward P/E 43.86
ILMN's Forward P/E is ranked lower than
83% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.70 vs. ILMN: 43.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 61.17
ILMN's PE(NRI) is ranked lower than
83% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.80 vs. ILMN: 61.17 )
Ranked among companies with meaningful PE(NRI) only.
ILMN' s PE(NRI) Range Over the Past 10 Years
Min: 34.06  Med: 75.76 Max: 332.54
Current: 61.17
34.06
332.54
Price/Owner Earnings (ttm) 52.60
ILMN's Price/Owner Earnings (ttm) is ranked lower than
78% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.25 vs. ILMN: 52.60 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ILMN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 20.62  Med: 59.33 Max: 6540
Current: 52.6
20.62
6540
P/B 12.74
ILMN's P/B is ranked lower than
94% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. ILMN: 12.74 )
Ranked among companies with meaningful P/B only.
ILMN' s P/B Range Over the Past 10 Years
Min: 2.88  Med: 7.59 Max: 23.59
Current: 12.74
2.88
23.59
P/S 11.48
ILMN's P/S is ranked lower than
91% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. ILMN: 11.48 )
Ranked among companies with meaningful P/S only.
ILMN' s P/S Range Over the Past 10 Years
Min: 3.62  Med: 9.36 Max: 17.2
Current: 11.48
3.62
17.2
PFCF 54.07
ILMN's PFCF is ranked lower than
79% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. ILMN: 54.07 )
Ranked among companies with meaningful PFCF only.
ILMN' s PFCF Range Over the Past 10 Years
Min: 13.75  Med: 45.62 Max: 136.79
Current: 54.07
13.75
136.79
POCF 39.18
ILMN's POCF is ranked lower than
81% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. ILMN: 39.18 )
Ranked among companies with meaningful POCF only.
ILMN' s POCF Range Over the Past 10 Years
Min: 10.67  Med: 34.35 Max: 341.94
Current: 39.18
10.67
341.94
EV-to-EBIT 45.16
ILMN's EV-to-EBIT is ranked lower than
80% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. ILMN: 45.16 )
Ranked among companies with meaningful EV-to-EBIT only.
ILMN' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.3  Med: 38.85 Max: 381.3
Current: 45.16
-61.3
381.3
EV-to-EBITDA 36.62
ILMN's EV-to-EBITDA is ranked lower than
80% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. ILMN: 36.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
ILMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.2  Med: 31 Max: 181.7
Current: 36.62
-77.2
181.7
PEG 2.49
ILMN's PEG is ranked higher than
63% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. ILMN: 2.49 )
Ranked among companies with meaningful PEG only.
ILMN' s PEG Range Over the Past 10 Years
Min: 1.21  Med: 2.98 Max: 13.34
Current: 2.49
1.21
13.34
Shiller P/E 198.97
ILMN's Shiller P/E is ranked lower than
100% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. ILMN: 198.97 )
Ranked among companies with meaningful Shiller P/E only.
ILMN' s Shiller P/E Range Over the Past 10 Years
Min: 152.28  Med: 555.68 Max: 3600
Current: 198.97
152.28
3600
Current Ratio 3.69
ILMN's Current Ratio is ranked higher than
73% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. ILMN: 3.69 )
Ranked among companies with meaningful Current Ratio only.
ILMN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 4.17 Max: 60.21
Current: 3.69
0.99
60.21
Quick Ratio 3.15
ILMN's Quick Ratio is ranked higher than
77% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. ILMN: 3.15 )
Ranked among companies with meaningful Quick Ratio only.
ILMN' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.89 Max: 60.21
Current: 3.15
0.87
60.21
Days Inventory 139.44
ILMN's Days Inventory is ranked lower than
59% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. ILMN: 139.44 )
Ranked among companies with meaningful Days Inventory only.
ILMN' s Days Inventory Range Over the Past 10 Years
Min: 93.73  Med: 119.41 Max: 147.41
Current: 139.44
93.73
147.41
Days Sales Outstanding 58.76
ILMN's Days Sales Outstanding is ranked higher than
56% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. ILMN: 58.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
ILMN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.76  Med: 67.64 Max: 86.41
Current: 58.76
56.76
86.41
Days Payable 131.66
ILMN's Days Payable is ranked higher than
86% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. ILMN: 131.66 )
Ranked among companies with meaningful Days Payable only.
ILMN' s Days Payable Range Over the Past 10 Years
Min: 51.84  Med: 62.29 Max: 131.66
Current: 131.66
51.84
131.66

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.70
ILMN's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. ILMN: -5.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ILMN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -184.6  Med: -5.75 Max: 0.6
Current: -5.7
-184.6
0.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 122.83
ILMN's Price/Net Current Asset Value is ranked lower than
98% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. ILMN: 122.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ILMN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.95  Med: 11.75 Max: 2050.89
Current: 122.83
1.95
2050.89
Price/Tangible Book 26.00
ILMN's Price/Tangible Book is ranked lower than
94% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. ILMN: 26.00 )
Ranked among companies with meaningful Price/Tangible Book only.
ILMN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.17  Med: 8.02 Max: 461.34
Current: 26
1.17
461.34
Price/Projected FCF 4.19
ILMN's Price/Projected FCF is ranked lower than
81% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. ILMN: 4.19 )
Ranked among companies with meaningful Price/Projected FCF only.
ILMN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.7  Med: 4.9 Max: 122.08
Current: 4.19
1.7
122.08
Price/Median PS Value 1.23
ILMN's Price/Median PS Value is ranked lower than
52% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. ILMN: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
ILMN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 0.97 Max: 70.91
Current: 1.23
0.44
70.91
Price/Peter Lynch Fair Value 2.45
ILMN's Price/Peter Lynch Fair Value is ranked lower than
51% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.22 vs. ILMN: 2.45 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ILMN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.73  Med: 2.76 Max: 9.54
Current: 2.45
1.73
9.54
Price/Graham Number 8.42
ILMN's Price/Graham Number is ranked lower than
87% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. ILMN: 8.42 )
Ranked among companies with meaningful Price/Graham Number only.
ILMN' s Price/Graham Number Range Over the Past 10 Years
Min: 3.51  Med: 6.95 Max: 49.18
Current: 8.42
3.51
49.18
Earnings Yield (Greenblatt) (%) 2.20
ILMN's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. ILMN: 2.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ILMN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 2.4 Max: 5.9
Current: 2.2
0.3
5.9
Forward Rate of Return (Yacktman) (%) 32.08
ILMN's Forward Rate of Return (Yacktman) (%) is ranked higher than
94% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. ILMN: 32.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ILMN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -7.7  Med: 1 Max: 38.1
Current: 32.08
-7.7
38.1

More Statistics

Revenue (TTM) (Mil) $2,314
EPS (TTM) $ 2.92
Beta0.75
Short Percentage of Float3.94%
52-Week Range $127.10 - 196.47
Shares Outstanding (Mil)146.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,485 2,814 3,151
EPS ($) 3.47 4.09 4.71
EPS w/o NRI ($) 3.47 4.09 4.71
EPS Growth Rate
(3Y to 5Y Estimate)
13.50%
Dividends Per Share ($)
» More Articles for NAS:ILMN

Headlines

Articles On GuruFocus.com
Ron Baron's Baron Funds Quarterly Report Aug 17 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Baron Funds Comments on Illumina Inc. Jul 13 2016 
Weekly CEO Sells Highlights Jun 28 2016 
Baron Funds Comments on Illumina Inc. May 23 2016 
Baron Funds Comments on Illumina May 06 2016 
Baron Funds Comments on Illumina Inc. Apr 26 2016 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Julian Robertson Keeps Buying Citigroup, Netflix, Facebook Dec 07 2015 
Halvorsen's Investment Makes Broadcom His Fifth-Most Valuable Stake Dec 05 2015 

More From Other Websites
Top 5 profitable Biotech stocks : September 23, 2016 Sep 23 2016
Illumina Faces a Bumpy Ride for a Few Quarters Sep 08 2016
Illumina to Webcast Live Presentation at the Morgan Stanley Global Healthcare Conference Aug 30 2016
ETF’s with exposure to Illumina, Inc. : August 29, 2016 Aug 29 2016
Illumina Keen on Genome Network Growth & Global Expansion Aug 26 2016
What’s behind Thermo Fisher’s Rumored Acquisition of Illumina? Aug 26 2016
Biotech building on the Peninsula bounces back — and it needs space to grow Aug 25 2016
Illumina Rallies on Rumors of Takeover by Thermo Fisher Aug 23 2016
Illumina downgraded by CL King Aug 22 2016
Artificial Intelligence, Machine Learning, And The FDA Aug 19 2016
Illumina Closes Slightly Up on Takeover Reports Aug 18 2016
Will Thermo Fisher Buy Illumina? Analyst Sees 'Close To A 0%' Chance Aug 18 2016
Illumina Shares Gain 2%, Cooling Speculation of a Thermo Fisher Buyout Aug 18 2016
Illumina (ILMN) Stock Gains on Thermo Fisher Takeover Speculation Aug 18 2016
Illumina Pops on Takeover -- One Chart Gives it Perspective Aug 18 2016
Illumina: Back in Bidness? Aug 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)